Stockpolly
Search
Delisting risk
ENSC · NASDAQ · Biotechnology

Ensysce Biosciences

Develops opioid-safety prodrugs and a neuroplastogenic pain candidate.

$0.3999
Pre-market+0.01 (+1.86%)
At close$0.3926(−1.83%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue000000000001
Cost of revenue200000000000
Gross profit−100000000001
1322−14224344
Research & development221124223432
111111111111
General & administrative111111111111
Other expenses−2−100−3−1−1−10−2−10
Operating income−3−3−2−21−4−2−2−4−3−4−3
00−1000000000
Interest expense001000000000
Other non-operating income000000000000
Income before tax−3−4−3−21−4−2−2−4−3−4−3
Net income from continuing operations−3−4−3−21−4−2−2−4−3−4−3
Net income−3−4−3−21−4−2−2−4−3−4−3
EPS, basic−$0.87−$1.55−$1.46−$0.98$1.00−$2.90−$1.39−$0.79−$1.29−$0.75−$0.52−$0.20
EPS, diluted−$0.87−$1.55−$1.46−$0.98$1.00−$2.90−$1.39−$0.79−$1.29−$0.51−$0.52−$0.20
Weighted average shares, basic3222211233713
Weighted average shares, diluted32222112326713
EBITDA0−3−2−21−4−2−2−4−3−4−3
Depreciation & amortization300000000000
EBIT−3−3−2−21−4−2−2−4−3−4−3